DR. ROBERT ALAN GREENWALD, MD
Osteopathic Medicine at Ohio Dr, New Hyde Park, NY
License number
New York 101466
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
2
2 Ohio Dr, New Hyde Park, NY 11042
5 Vauxhall Ct, Huntington Station, NY 11747
5 Vauxhall Ct, Huntington Station, NY 11747
Phone
(516) 622-6086
(516) 390-5768 (Fax)
(631) 643-6655
(631) 253-0471 (Fax)
(516) 390-5768 (Fax)
(631) 643-6655
(631) 253-0471 (Fax)
Professional information
Composition Comprising Non-Steroidal Anti-Inflammatory Agent Tenidap And Effectively Non-Antibacterial Tetracycline
US Patent:
5308839, May 3, 1994
Filed:
Sep 4, 1992
Appl. No.:
7/940540
Inventors:
Lorne M. Golub - Smithtown NY
Thomas F. McNamara - Port Jefferson NY
Robert A. Greenwald - Melville NY
Thomas F. McNamara - Port Jefferson NY
Robert A. Greenwald - Melville NY
Assignee:
The Research Foundation of State University of New York - Albany NY
International Classification:
A61K 3165, A61K 3140
US Classification:
514152
Abstract:
A method for treating mammals suffering from rheumatoid arthritis, other tissue-destructive conditions, and chronic inflammatory or other conditions associated with excess metalloproteinase activity comprising administering to the mammal an amount of a tetracycline that is effectively anti-metalloproteinase, but that is not effectively antimicrobial, and an amount of a non-steroidal anti-inflammatory agent which, when combined with the effectively anti-metalloproteinase amount of tetracycline, results in a significant reduction of tissue destruction and/or bone loss.
Robert Alan Greenwald, New Hyde Park NY
Specialties:
Internal Medicine, Rheumatology
Work:
Prohealth Care Associates Llp
2 Ohio Dr, New Hyde Park, NY 11042 Long Island Jewish Medical Center
2800 Marcus Ave, New Hyde Park, NY 11042 Long Island Jewish Medical Center
410 Lakeville Rd, New Hyde Park, NY 11042 North Shore University Hospital
300 Community Dr, Manhasset, NY 11030
2 Ohio Dr, New Hyde Park, NY 11042 Long Island Jewish Medical Center
2800 Marcus Ave, New Hyde Park, NY 11042 Long Island Jewish Medical Center
410 Lakeville Rd, New Hyde Park, NY 11042 North Shore University Hospital
300 Community Dr, Manhasset, NY 11030
Education:
Johns Hopkins University (1967)
Robert Alan Greenwald, New Hyde Park NY
Specialties:
Rheumatologist
Address:
2 Ohio Dr, New Hyde Park, NY 11042
27005 76Th Ave, New Hyde Park, NY 11040
2800 Marcus Ave, New Hyde Park, NY 11042
27005 76Th Ave, New Hyde Park, NY 11040
2800 Marcus Ave, New Hyde Park, NY 11042
Education:
Johns Hopkins University, School of Medicine - Doctor of Medicine
Zucker Hillside Hospital, The - Residency - Family Medicine
Zucker Hillside Hospital, The - Residency - Family Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Rheumatology (Internal Medicine)
Method Of Using Tetracycline Compounds For Inhibition Of Endogenous Nitric Oxide Production
US Patent:
5789395, Aug 4, 1998
Filed:
Aug 30, 1996
Appl. No.:
8/697815
Inventors:
Ashok R. Amin - Union NJ
Steven B. Abramson - Rye NY
Lorne M. Golub - Smithtown NY
Nungavaram S. Ramamurthy - Smithtown NY
Thomas F. McNamara - Port Jefferson NY
Robert A. Greenwald - Melville NY
Howard Trachtman - New Rochelle NY
Steven B. Abramson - Rye NY
Lorne M. Golub - Smithtown NY
Nungavaram S. Ramamurthy - Smithtown NY
Thomas F. McNamara - Port Jefferson NY
Robert A. Greenwald - Melville NY
Howard Trachtman - New Rochelle NY
Assignee:
The Research Foundation of State University of New York - Albany NY
Hospital for Joint Diseases - New York NY
Hospital for Joint Diseases - New York NY
International Classification:
A61K 3165, C12N 999, C12N 904, C12N 906
US Classification:
514152
Abstract:
A method is disclosed for inhibiting endogenous production of nitric oxide (NO) in an in vivo, in vitro, or ex vivo mammalian system. The method employs a tetracycline compound to inhibit production of NO and/or to inhibit the expression or activity of an inducible isoform of nitric oxide synthase (iNOS). Preferably, the tetracycline compound has inhibitory activity for metalloproteinases. Also it is preferred that the tetracycline compound is provided to the mammalian system in an amount which has little or no antibacterial activity in the system. Accordingly, preferred tetracycline compounds are tetracycline compounds which have be modified to reduce or eliminate their antimicrobial activity. The method can be used to treat medical conditions in mammals characterized by NO production mediated by iNOS, including, for example, inflammatory conditions.
Inhibition Of Wasting And Protein Degradation Of Mammalian Muscle By Tetracyclines
US Patent:
5045538, Sep 3, 1991
Filed:
Jun 28, 1990
Appl. No.:
7/545395
Inventors:
Bruce Schneider - Great Neck NY
Robert A. Greenwald - Melville NY
Jonathan Maimon - Rego Park NY
Kenneth Gorray - Fresh Meadows NY
Lorne M. Golub - Smithtown NY
Thomas F. McNamara - Port Jefferson NY
Robert A. Greenwald - Melville NY
Jonathan Maimon - Rego Park NY
Kenneth Gorray - Fresh Meadows NY
Lorne M. Golub - Smithtown NY
Thomas F. McNamara - Port Jefferson NY
Assignee:
The Research Foundation of State University of New York - Albany NY
International Classification:
A61K 3165
US Classification:
514152
Abstract:
A method for treating mammals suffering from skeletal muscle wasting and/or intracellular protein degradation of skeletal muscle systems by administering to the mammal an amount of tetracycline which results in a significant reduction of the muscle wasting and protein degradation is disclosed. In addition, there is also disclosed a method of increasing the protein content of skeletal muscle systems of mammals by administration of tetracyclines. The tetracyclines useful in the above methods are both antimicrobial and non-antimicrobial. In a preferred embodiment, the method of treatment utilizes a non-antimicrobial tetracycline such as dedimethylaminotetracycline (CMT).
Method Of Using Tetracycline Compounds To Enhance Interleukin-10 Production
US Patent:
6015804, Jan 18, 2000
Filed:
Sep 11, 1998
Appl. No.:
9/151534
Inventors:
Lorne M. Golub - Smithtown NY
Christopher T. Ritchlin - Canandaigua NY
Robert A. Greenwald - Melville NY
Susan A. Moak - Bayside NY
Hsi-Ming Lee - Setauket NY
Christopher T. Ritchlin - Canandaigua NY
Robert A. Greenwald - Melville NY
Susan A. Moak - Bayside NY
Hsi-Ming Lee - Setauket NY
Assignee:
The Research Foundation of State University of New York - Albany NY
University of Rochester - Rochester NY
University of Rochester - Rochester NY
International Classification:
A61K 3165
US Classification:
514152
Abstract:
The invention is a method of enhancing endogenous interleukin-10 production in mammalian cells and tissues, which includes administering an effective amount of a tetracycline derivative. The method also includes enhancing interleukin-10 production by administering an effective amount of the tetracycline derivative to a mammal. Preferred tetracycline compounds are tetracycline compounds which have been modified to reduce or eliminate their antimicrobial activity. The method can be used to treat medical conditions in mammals characterized by excessive IL-1 and TNF. alpha. production.
Inhibition Of Excessive Phospholipase A.sub.2 Activity And/Or Production By Non-Antimicrobial Tetracyclines
US Patent:
5523297, Jun 4, 1996
Filed:
Apr 21, 1995
Appl. No.:
8/426899
Inventors:
Waldemar Pruzanski - Toronto, CA
Lorne M. Golub - Smithtown NY
Peter Vadas - Toronto, CA
Robert A. Greenwald - Melville NY
Thomas F. McNamara - Port Jefferson NY
Lorne M. Golub - Smithtown NY
Peter Vadas - Toronto, CA
Robert A. Greenwald - Melville NY
Thomas F. McNamara - Port Jefferson NY
Assignee:
The Research Foundation of State University of New York - Albany NY
International Classification:
A61K 3165
US Classification:
514152
Abstract:
A method for treating mammals suffering from conditions associated with excess phospholipase A. sub. 2 activity and/or production comprising administering to the mammal an effective amount of a non-antimicrobial tetracycline sufficient to inhibit excess phospholipase A. sub. 2 activity and/or production is disclosed.
Method For Reducing C-Rective Protein Levels With Non-Antibacterial Tetracycline Formulations
US Patent:
2005028, Dec 22, 2005
Filed:
Jul 11, 2003
Appl. No.:
10/519534
Inventors:
David Brown - Bronxville NY, US
Lorne Golub - Smithtown NY, US
Hsi-Ming Lee - Setauket NY, US
Robert Greenwald - Melville NY, US
Lorne Golub - Smithtown NY, US
Hsi-Ming Lee - Setauket NY, US
Robert Greenwald - Melville NY, US
International Classification:
A61K031/65
US Classification:
514152000
Abstract:
The present invention is for a method for decreasing C-reactive protein levels (CRP) in a mammal in need thereof. The method comprises administering an effective amount of a non-antibacterial tetracycline formulation, to the mammal. In one embodiment, the non-antibacterial tetracycline formulation is a non-antibacterial amount of an antibacterial tetracycline. In another embodiment, the non-antibacterial tetracycline formulation is a non-antibacterial tetracycline.
Inhibition Of Excessive Phospholipase A.sub.2 Activity And/Or Production By Non-Antimicrobial Tetracyclines
US Patent:
6043231, Mar 28, 2000
Filed:
Aug 31, 1993
Appl. No.:
8/115158
Inventors:
Waldemar Pruzanski - Toronto, CA
Lorne M. Golub - Smithtown NY
Peter Vadas - Toronto, CA
Robert A. Greenwald - Melville NY
Thomas F. McNamara - Port Jefferson NY
Lorne M. Golub - Smithtown NY
Peter Vadas - Toronto, CA
Robert A. Greenwald - Melville NY
Thomas F. McNamara - Port Jefferson NY
Assignee:
The Research Foundation of State Univ. of New York - Albany NY
International Classification:
A61K 3165
US Classification:
514152
Abstract:
A method for treating mammals suffering from conditions associated with excess phospholipase A. sub. 2 activity and/or production comprising administering to the mammal an effective amount of a non-antimicrobial tetracycline sufficient to inhibit excess phospholipase A. sub. 2 activity and/or production is disclosed. A pharmaceutical composition is also disclosed.
Method For Decreasing Low Density Lipoprotein
US Patent:
6841547, Jan 11, 2005
Filed:
Feb 28, 2003
Appl. No.:
10/377088
Inventors:
David Brown - Bronxville NY, US
Lorne M. Golub - Smithtown NY, US
Hsi-Ming Lee - Setauket NY, US
Robert Greenwald - Melville NY, US
Maria Ryan - Huntington NY, US
Kavita Desai - Bronx NY, US
Lorne M. Golub - Smithtown NY, US
Hsi-Ming Lee - Setauket NY, US
Robert Greenwald - Melville NY, US
Maria Ryan - Huntington NY, US
Kavita Desai - Bronx NY, US
Assignee:
Albert Einstein College of Medicine of Yeshevia University - Bronx NY
Montefiore Medical Center - Bronx NY
The Research Foundation of State University of New York - Albany NY
Montefiore Medical Center - Bronx NY
The Research Foundation of State University of New York - Albany NY
International Classification:
A61K 3165
US Classification:
514152
Abstract:
The present invention relates to a method for decreasing elevated serum/plasma LDL-cholesterol levels or LDL-cholesterol levels and CRP levels in a mammal in need thereof. The methods comprises administering an effective amount of a tetracycline formulation. In one embodiment, the tetracycline formulation is a non-antibacterial tetracycline. In another embodiment, the tetracycline formulation is an antibacterial tetracycline at a sub-antibacterial amount.